Skip to content

Green Coffee Extract Supplementation and Oxidative Stress, Systemic and Vascular Inflammation

Effects of Green Coffee Extract Supplementation on Oxidative Stress, Systemic and Vascular Inflammation in Patients With Metabolic Syndrome: A Randomized Clinical Trial

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03265184
Enrollment
48
Registered
2017-08-29
Start date
2017-01-01
Completion date
2017-07-18
Last updated
2017-08-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metabolic Syndrome

Brief summary

Metabolic syndrome (Mets) is defined as the collection of risk factors contributing to type 2 diabetes mellitus and cardiovascular disease. Mets is accompanied by oxidative stress and low-grade inflammation. Green coffee is rich in polyphenols called chlorogenic acids (CGA) which possess anti-inflammatory and anti-oxidative characteristics. Thus, we carried out this trial to examine green coffee extract (GCE) effects on oxidative stress, systemic and vascular inflammation in patients having Mets

Interventions

DIETARY_SUPPLEMENTgreen coffee extract

Patients in treatment group take 400 mg GCE supplements twice a day for tow month

Sponsors

National Nutrition and Food Technology Institute
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
DOUBLE (Subject, Caregiver)

Eligibility

Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

* body mass index of over 25, waist circumference \>102 cm in men or \>88 cm in women,Fasting blood glucose \>100 mg/dL, Triglycerides (TG) \> 150 mg/dL, High density lipoprotein cholesterol (HDL-C) \<50 in women or \<40 in men, Systolic blood pressure (SBP) \>130 mmHg and diastolic blood pressure (DBP) \>85mmHg

Exclusion criteria

* insulin administration for diabetes control, having hypo- or hyperthyroidism, renal failure or other chronic diseases, regular coffee consumption, pregnancy, breastfeeding, taking estrogen, progesterone, corticosteroids, weight loss supplements and obeying unusual weight loss plans

Design outcomes

Primary

MeasureTime frame
intercellular adhesion molecule-1 (ICAM-1)8 weeks
interleukin-6 (IL-6)8 weeks
high sensitivity C-reactive protein (hs-CRP)8 weeks
malondialdehyde (MDA)8 weeks

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026